Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

We studied the effects of combined chemotherapy with doxorubicin/docetaxel on erythroid and granulocytic hematopoietic lineages with particular attention focused on their recovery in patients with stages III-IV breast cancer. Intensification of differentiation of erythroid and granulocytic CFU (even under conditions of their suppressed proliferation) provided the increase in the content of mature and morphologically differentiated elements in the bone marrow and peripheral blood. High proliferative activity of erythroid and granulomonocytic precursors resulted from enhanced production of hematopoiesis-stimulating activities by microenvironment elements.

About the authors

V. E. Goldberg

Research Institute of Oncology

Author for correspondence.
Email: goldbergve@mail.ru
Russian Federation, Tomsk

T. Yu. Polyakova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University, Ministry of Health of Russian Federation

Email: goldbergve@mail.ru
Russian Federation, Tomsk; Tomsk

N. O. Popova

Research Institute of Oncology

Email: goldbergve@mail.ru
Russian Federation, Tomsk

V. V. Vysotskaya

Research Institute of Oncology

Email: goldbergve@mail.ru
Russian Federation, Tomsk

E. I. Simolina

Research Institute of Oncology

Email: goldbergve@mail.ru
Russian Federation, Tomsk

E. A. Dudnikova

Research Institute of Oncology

Email: goldbergve@mail.ru
Russian Federation, Tomsk

N. M. Goncharova

Research Institute of Oncology

Email: goldbergve@mail.ru
Russian Federation, Tomsk

Yu. V. Belevich

Research Institute of Oncology

Email: goldbergve@mail.ru
Russian Federation, Tomsk

E. G. Grigor’ev

Research Institute of Oncology

Email: goldbergve@mail.ru
Russian Federation, Tomsk

A. V. Goldberg

Research Institute of Oncology

Email: goldbergve@mail.ru
Russian Federation, Tomsk

A. M. Dygai

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: goldbergve@mail.ru
Russian Federation, Tomsk


Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies